It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hyperalgesia often occurs in alcoholics, especially during abstinence, yet the underlying mechanisms remain elusive. The lateral habenula (LHb) has been implicated in the pathophysiology of pain and alcohol use disorders. Suppression of m-type potassium channels (M-channels) has been found to contribute to the hyperactivity of LHb neurons of rats withdrawn from chronic alcohol administration. Here, we provided evidence that LHb M-channels may contribute to hyperalgesia. Compared to alcohol naïve counterparts, in male Long-Evans rats at 24-hours withdrawal from alcohol administration under the intermittent access paradigm for eight weeks, hyperalgesia was evident (as measured by paw withdrawal latencies in the Hargreaves Test), which was accompanied with higher basal activities of LHb neurons in brain slices, and lower M-channel protein expression. Inhibition of LHb neurons by chemogenetics, or pharmacological activation of M-channels, as well as overexpression of M-channels’ subunit KCNQ3, relieved hyperalgesia and decreased relapse-like alcohol consumption. In contrast, chemogenetic activation of LHb neurons induced hyperalgesia in alcohol-naive rats. These data reveal a central role for the LHb in hyperalgesia during alcohol withdrawal, which may be due in part to the suppression of M-channels and, thus, highlights M-channels in the LHb as a potential therapeutic target for hyperalgesia in alcoholics.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The State University of New Jersey, New Jersey Medical School, Department of Anesthesiology, Rutgers, Newark, USA (GRID:grid.469131.8) (ISNI:0000 0000 8692 8176); The State University of New Jersey, New Jersey Medical School, Pharmacology, Physiology, and Neuroscience, Rutgers, Newark, USA (GRID:grid.469131.8) (ISNI:0000 0000 8692 8176); Mayo Clinic College of Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
2 The State University of New Jersey, New Jersey Medical School, Department of Anesthesiology, Rutgers, Newark, USA (GRID:grid.469131.8) (ISNI:0000 0000 8692 8176); The State University of New Jersey, New Jersey Medical School, Pharmacology, Physiology, and Neuroscience, Rutgers, Newark, USA (GRID:grid.469131.8) (ISNI:0000 0000 8692 8176)